OE33
OE33
Cell Line Name
Cell Line Description
The cell line OE33, also known as JROECL33, was established from the adenocarcinoma of the lower oesophagus (Barrett's metaplasia) of a 73 year old female patient. The tumour was identified as pathological stage IIA (UICC) and showed poor differentiation. OE33 express HLA-A, -B and -C antigens (MHC class I) and ICAM-1 constitutively. Expression of HLA-DR (MHC class II) can be induced by treatment with interferon-gamma. The cells express epithelial cytokeratins and are tumourigenic in nude mice.Cultures derived from ECACC stocks of this cell line have been whole genome sequenced (Contino et al 2016) confirming the presence of many of the known mutations that drive oesophageal cancer
General Info
Species
Human
Links
Cellosaurus: CVCL_0471
Release Conditions
Characteristics
Receptors
Tissue of Origin
DNA profile (STR Profile)
Amelogenin: X
CSF1PO: 10
D5S818: 11
D7S820: 9,10
D13S317: 14
D16S539: 12
TH01: 7,8
TPOX: 8,11
vWA: 17
Karyotype
Applications
Study of oesophageal cancer
Disease
Culture Conditions
Cell Type
Subculture Routine
Split sub-confluent cultures (70-80%) 1:8 i.e. seeding at 1x10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Initially these cells grow slowly and can take up to 7 days until ready for the next split, 50% media changes will be necessary every 2-3 days (i.e. replacing half the old medium with fresh).
Culture Medium
RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Growth Mode
Additional Info
Depositor
Country of Origin
Hazard Group (ACDP)
Applications
References
Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR 1997 Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer. 75(2):258-63 PMID: 9010035Whole-genome sequencing of nine esophageal adenocarcinoma cell lines
Bibliography
Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN. 2010 Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 102(4):271-4.PMID: 20075370. Barretina J, et al., 2012 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483(7391):603-7. PMID: 22460905.
Available Formats
- Frozen
- DNA-5µg (100ng/µl)
Citation Guidance
If use of this culture results in a scientific publication, it should be cited in the publication as: OE33 (ECACC 96070808).
Biosafety Information
Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Further Information
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.